Effects of Exercise in People With Paraplegia
Exercise Treatment of Obesity-Related Secondary Conditions in Adults With Paraplegia
1 other identifier
interventional
32
1 country
1
Brief Summary
This hypothesis-driven study will investigate effects of physical activity with or without a nutrient supplement known to increase body lean mass in adults with chronic paraplegia who have clusters of obesity and obesity-related secondary complications.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Oct 2008
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 1, 2008
CompletedFirst Submitted
Initial submission to the registry
September 15, 2010
CompletedFirst Posted
Study publicly available on registry
September 16, 2010
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 1, 2012
CompletedStudy Completion
Last participant's last visit for all outcomes
September 1, 2012
CompletedMarch 24, 2015
March 1, 2015
3.9 years
September 15, 2010
March 23, 2015
Conditions
Outcome Measures
Primary Outcomes (1)
Global cardiovascular disease risk score
Global cardiovacular disease risk will be generated by evaluating blood metabolism in the fasting and fed state for inflammatory disease markers including total cholesterol: high density lipoprotein ratio (TC: HDL ratio), post-prandial lipemia (PPL), whole body fat oxidation (WBFO), insulin resistance, and inflammatory mediators.
4 visits over 9 months
Secondary Outcomes (3)
Body composition
4 visits over 9 months
Cardiovascular Endurance
4 visits over 9 months
Muscular strength
8 visits over 9 months
Study Arms (2)
Supplement
EXPERIMENTALParticipants randomized to the 'supplement' arm will consume a blended drink containing 48g of ionexchange, hydrolyzed vanilla-flavored whey protein (Whey to Go, Solgar Vitamin and Herb, Leonia, NJ; 3g CH2O, \< 3g Total Fat). The drink will be given in split doses immediately before and after each training session, which represents a timing schedule that best stimulates muscle anabolism in persons undergoing exercise training.
Placebo
PLACEBO COMPARATORAs ingestion of the protein supplement is critically influenced by time of administration, participants assigned to the 'placebo' study arm will consume the identical supplement and dose on days during which training is not performed. This strategy will allow the groups to be isocaloric and equal in protein supplementation.
Interventions
CRT will occur 3 times per week for 26 weeks. Each training session will last approximately 40-45 minutes and employ resistance training (weight lifting) and high-speed, low intensity endurance activities (arm cranking) with interposed periods of incomplete recovery (i.e., heart rate not falling to baseline).
Eligibility Criteria
You may qualify if:
- SCI resulting in paraplegia between T5 and L1
- injury for more than one year
- American Spinal Injury Association Impairment Scale (AIS) grade A-C injuries
- BMI ≥ 23 kg/m2 (defined by studies as the equivalent to the WHO criterion of 25 kg/m2 as 'overweight', and the point at which health risks begin to increase), plus any two or more of the following conditions on screening:
- prehypertension (BP ≥ 120/80 mmHg) by updated AHA and ADA criteria
- dyslipidemia (HDL-C ≥ 40 mg/dL or TG ≤ 150 mg/dL) by NCEP ATP III Guidelines,44 or
- impaired fasting glucose (≥ 100 mg/dL) by 2006 ADA criteria.
You may not qualify if:
- surgery within 6 months
- pressure ulcer within 3 months
- upper limb pain that limits exercise
- recurrent acute infection or illness requiring hospitalization or IV antibiotics
- pregnancy
- previous myocardial infarction or cardiac surgery
- month history of glucose lowering and lipid-lowering drug therapy
- Type I or II diabetes (by WHO criteria)
- daily intake of vitamin supplements exceeding 100% RDA
- The following medications and drug therapies will disqualify subjects from participating: beta-adrenergic antagonists, maintenance alpha-blockers, Methyldopa, thiazide and loop diuretics, parasympatholytic agents, zinc, estrogen/hormone replacement therapy excluding oral contraceptives, insulin-sensitizing drugs, and maintenance use of aspirin and nonsteroidal anti-inflammatory drugs.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
The Miami Project to Cure Paralysis
Miami, Florida, 33136, United States
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Mark S Nash, PhD
University of Miami Miller School of Medicine, The Miami Project to Cure Paralysis
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- PREVENTION
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
September 15, 2010
First Posted
September 16, 2010
Study Start
October 1, 2008
Primary Completion
September 1, 2012
Study Completion
September 1, 2012
Last Updated
March 24, 2015
Record last verified: 2015-03